BNGO BIONANO GENOMICS INC

Bionano to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Bionano to Present at the H.C. Wainwright 27th Annual Global Investment Conference

SAN DIEGO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano’s president and chief executive officer, will present at the H.C. Wainwright 27th Annual Global Investment Conference on Monday, September 8th, 2025.

Conference & Webcast Details

Date:September 8, 2025
Time:3:00 p.m. to 3:30 p.m. ET
Presenter:Erik Holmlin, PhD, CEO of Bionano
Webcast:
  

A replay / recording of the session will be available following the conference through the Bionano website at  for at least 30 days.

About Bionano

Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through optical genome mapping (OGM) solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. The Company also offers an industry-leading, platform-agnostic genome analysis software solution, and nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also offers OGM-based diagnostic testing services.

For more information, visit  or .

Bionano’s products are for research use only and not for use in diagnostic procedures.

Contacts

Company Contact:

Erik Holmlin, CEO

Bionano Genomics, Inc.

+1 (858) 888-7610

Investor Relations:

Kelly Gura

Gilmartin Group

+1 (212) 229-6163



EN
25/08/2025

Underlying

BNGOBIONANO GENOMICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BIONANO GENOMICS INC

 PRESS RELEASE
Free
BNGO BIONANO GENOMIC...

Bionano Genomics, Inc. Announces Closing of $10 Million Public Offering

Bionano Genomics, Inc. Announces Closing of $10 Million Public Offering SAN DIEGO, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) (“Bionano” or the “Company”) today announced the closing of its previously announced public offering of an aggregate of 5,000,000 shares of the Company’s common stock (or common stock equivalents in lieu thereof), Series E warrants to purchase up to 5,000,000 shares of the Company’s common stock and short-term Series F warrants to purchase up to 5,000,000 shares of the Company’s common stock (all the warrants, collectively, the “Series ...

1h / 2m 1 EN
 PRESS RELEASE
Free
BNGO BIONANO GENOMIC...

Bionano Genomics, Inc. Announces Pricing of $10 Million Public Offering

Bionano Genomics, Inc. Announces Pricing of $10 Million Public Offering SAN DIEGO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) (“Bionano” or the “Company”) today announced the pricing of a public offering of an aggregate of 5,000,000 shares of the Company’s common stock (or common stock equivalents in lieu thereof), Series E warrants to purchase up to 5,000,000 shares of the Company’s common stock and short-term Series F warrants to purchase up to 5,000,000 shares of the Company’s common stock (all the warrants, collectively, the “Series Warrants”), at a combin...

September 16, 2025 1 EN
 PRESS RELEASE
Free
BNGO BIONANO GENOMIC...

Multiple Studies Highlighting OGM Utility For Analysis of Cancer Bioma...

Multiple Studies Highlighting OGM Utility For Analysis of Cancer Biomarker Chromoanagenesis Published in Dedicated Issue of Methods in Molecular Biology SAN DIEGO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that an issue of the book series Methods in Molecular Biology dedicated to studies of the catastrophic genome rearrangement known as chromoanagenesis was published with multiple studies highlighting the advantages of optical genome mapping (OGM) in chromoanagenesis research. According to research, chromoanagenesis refers to a catastrophic ...

September 16, 2025 1 EN
 PRESS RELEASE
Free
BNGO BIONANO GENOMIC...

CMS Posts Preliminary Payment Determination for New Category I CPT Cod...

CMS Posts Preliminary Payment Determination for New Category I CPT Code Covering Use of OGM for Constitutional Genetic Disorders SAN DIEGO, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (Nasdaq: BNGO) offering CLIA-certified laboratory developed tests (LDTs) based on optical genome mapping (OGM), today announced that Centers for Medicare & Medicaid Services (CMS) posted the preliminary payment determination for the Category I Current Procedural Terminology (CPT®) code for use of OGM in cytogenomic genome-wide analysis to detec...

September 15, 2025 1 EN
 PRESS RELEASE
Free
BNGO BIONANO GENOMIC...

Bionano to Present at the H.C. Wainwright 27th Annual Global Investmen...

Bionano to Present at the H.C. Wainwright 27th Annual Global Investment Conference SAN DIEGO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano’s president and chief executive officer, will present at the H.C. Wainwright 27th Annual Global Investment Conference on Monday, September 8th, 2025. Conference & Webcast Details Date:September 8, 2025Time:3:00 p.m. to 3:30 p.m. ETPresenter:Erik Holmlin, PhD, CEO of BionanoWebcast:   A replay / recording of the session will be available following the conference through ...

August 25, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch